Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2018-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02163759

Ulcerative Colitis

COMPLETED PHASE3

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03653026

Ulcerative Colitis (UC)

COMPLETED PHASE3

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

NCT03038711

Ulcerative Colitis

COMPLETED PHASE1

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02171429

Ulcerative Colitis

COMPLETED PHASE3

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622

Ulcerative Colitis (UC)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis, Active Moderate Ulcerative Colitis, Active Severe

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bertilimumab

Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes

Group Type EXPERIMENTAL

Bertilimumab

Intervention Type BIOLOGICAL

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Placebo

Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bertilimumab

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Intervention Type BIOLOGICAL

Placebo

IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females, 18 to 70 years of age inclusive.
2. Diagnosed with active moderate to severe UC per standard diagnostic criteria for a minimum of 3 months:

* Mayo score of 6-12 (inclusive) at the Screening Visit
* Endoscopic evidence of active mucosal disease, as assessed by flexible sigmoidoscopy, with an Endoscopic Finding Sub-score of ≥2 (assessed centrally)
* Rectal Bleeding Sub-score of ≥1
* Physician's Global Assessment (PGA) Sub-score of ≥2.
3. Levels of eotaxin-1 in biopsied colon tissue of ≥100 pg/mg protein.
4. Adequate cardiac, renal and hepatic function as determined by the Investigator and demonstrated by screening laboratory evaluations and physical examination results; these findings must all be within normal limits or judged not clinically significant by the Investigator.

Exclusion Criteria

1. History of colonic or rectal surgery other than hemorrhoidal surgery or appendectomy.
2. Currently receiving total parenteral nutrition (TPN).
3. Positive Clostridium difficile toxin stool assay.
4. Tested positive for active/latent mycobacterium tuberculosis (TB) infection.
5. Pregnant or breast-feeding, or plan to become pregnant during the study.
6. Males who are young and childless or planning to have more children in the future.
7. Known hypersensitivity to bertilimumab or any of the drug excipients.
8. History of infection requiring administration of any IV antibiotic, antiviral or antifungal medication within 30 days of Screening or any oral anti-infective agent within 14 days of Screening.
9. Severe UC evidenced by the following signs of toxicity: heart rate \>100 beats/min at rest, temperature \>37.8°C, hemoglobin \<10.0 g/dL.
10. Ulcerative proctitis, defined as disease limited to less than 15 cm from the anal verge.
11. Received a vaccine or other immunostimulator within 4 weeks prior to screening.
12. Use of \>4.8 g mesalazine or equivalent within 2 weeks prior to the screening visit. Mesalazine ≤4.8 g is allowed if the dose during the 2 weeks prior to the screening visit was stable.
13. Use of systemic corticosteroids exceeding the equivalent of 20 mg/day of prednisone within four weeks prior to the screening visit (see Section 6.9.1).
14. Change in dose of immunosuppressive drugs (e.g., corticosteroids, 6-mercaptopurine \[6-MP\], azathioprine) within four weeks prior to the screening visit.
15. Use of TNF-blockers (e.g., infliximab or adalimumab) within 60 days of the screening visit.
16. Use of chronic non-steroidal anti-inflammatory (NSAID) therapy. Occasional use of NSAIDs or acetaminophen for headache, arthritis, myalgias, menstrual cramps, etc., or daily use of low dose (81-162 mg) aspirin for cardiovascular prophylaxis is allowed.
17. Patients diagnosed with:

* Crohn's disease
* Diverticulitis or diverticulosis
* Indeterminate colitis (inability to distinguish between UC and Crohn's disease \[as assessed by the Investigator\])
* Microscopic colitis (collagenous or lymphocytic colitis)
* Ischemic or infectious colitis
* Clostridium difficile colitis within 90 days of the screening visit
* Parasitic disease within 90 days of the screening visit
* Systemic fungal infection within 90 days of the screening visit.
18. History of positive serology of hepatitis B or C, or human immunodeficiency virus (HIV) infection.
19. Congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, organ transplantation).
20. Clinically significant abnormal laboratory test results, unless regarded by the Investigator as related to UC, including but not limited to:

* Hemoglobin level \<10.0 g/dL
* White blood cell count \< 3 x 103/µL
* Lymphocyte count \< 0.5 x 103/µL
* Platelet count \<100 x 103/µL or \>1200 x 103/µL
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 the upper limit of normal (ULN)
* Alkaline phosphatase \>3 ULN
* Serum creatinine \>2 ULN.
21. Active abuse of alcohol or drugs.
22. Known malignancy or history of malignancy that could reduce life expectancy.
23. Any condition, which in the opinion of the Investigator, would place the patient at an unacceptable risk if participating in the study protocol.
24. Participation in a clinical trial of an investigational (unapproved) product

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No